Another Attack on the Carve-Out: Novartis Seeks a TRO Enjoining ENTRESTO Generic
FDA Law Blog: Biosimilars
AUGUST 7, 2024
ENTRESTO was approved by FDA in July 2015 “to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.”
Let's personalize your content